Most of what gets written about kava focuses on what it feels like. Relaxed. Social. Clear-headed. Not drunk. These descriptions are accurate but they skip the more interesting question: what is actually happening in the brain to produce those effects? In 2023, a research team in Australia got closer to answering that than anyone had before, by putting kava recipients in an MRI scanner and measuring their brain chemistry directly. This issue looks at what they found, why GABA matters, and how kava compares to other compounds that work on the same system.

Part One

GABA: your brain's brake pedal

Why it matters for anxiety, relaxation, and social ease

Gamma-aminobutyric acid (GABA) is the primary inhibitory neurotransmitter in the central nervous system. Where excitatory neurotransmitters like glutamate ramp neural activity up, GABA brings it down. When GABA binds to its receptors, the effect is broadly calming — reduced anxious arousal, slower heart rate, quieter mental activity. Low GABAergic tone is associated with anxiety disorders. High GABAergic tone is associated with relaxation, and in excessive doses, sedation.

This is the same system that alcohol, benzodiazepines, and barbiturates all act on — though through different mechanisms and with very different consequences. Alcohol directly binds to GABA-A receptors and floods the system broadly. This is why it reduces social inhibition and anxiety quickly, but also why it impairs coordination and memory, produces hangovers, and drives physical dependence with repeated use. The GABA system is effective at producing the social ease people are often looking for. The problem has always been the delivery mechanism.

Kava's active compounds, kavalactones, appear to interact with the GABA system too — but differently. Rather than directly binding to GABA receptors the way alcohol does, kavalactones appear to modulate GABA-A receptor activity indirectly, enhancing GABA's effect without the same broad, system-wide suppression. Early clinical data showed the behavioral result: reduced anxiety, social ease, no meaningful cognitive impairment, no hangover. What was missing until recently was a direct look inside the brain to see what was actually changing.

The key distinction: Alcohol produces GABAergic effects by blunt force — directly binding receptors system-wide. Kavalactones appear to modulate the same system more selectively. The clinical outcomes are meaningfully different: comparable reduction in anxiety, without the cognitive and physical side effects.
Part Two

The first brain imaging study of kava

Savage, Sarris et al., Nutrients, 2023

Prior to 2023, the evidence for kava's mechanism of action came largely from binding studies and clinical trials measuring behavioral outcomes — anxiety scores, self-reported stress, sleep quality. Researchers knew kava reduced anxiety. They had reasonable hypotheses about why. But nobody had looked directly at brain chemistry in a clinical sample to confirm what was happening at the neurobiological level.

That changed with a study published in Nutrients in October 2023 by Savage, Sarris, and colleagues at Swinburne University of Technology and the Florey Institute of Neuroscience in Melbourne. The study used proton magnetic resonance spectroscopy (MRS) — a brain imaging technique that can measure the concentration of specific neurochemicals in targeted brain regions — to assess GABA levels in the dorsal anterior cingulate cortex (dACC) before and after kava treatment in adults with a clinical diagnosis of Generalized Anxiety Disorder.

The dACC is a region of particular interest in anxiety research. It sits at the intersection of the brain's emotional processing and cognitive control networks, and elevated GABA levels in this region have been observed in people with clinical anxiety. The study was designed to test whether kava changed those levels, and whether the changes tracked with treatment response.

"The assessment of the neurobiological effects of kava is novel in GAD samples and shows how our methodology could be applied to other anxiolytic phytomedicines."
Savage et al., Nutrients, 2023
Clinical Evidence  ·  Savage et al., 2023
Study Design
Neuroimaging sub-study conducted within the larger Kava for GAD (KGAD) clinical trial (ClinicalTrials.gov: NCT02219880). 37 adult participants with a formal diagnosis of Generalized Anxiety Disorder received either kava standardized to 120 mg kavalactones twice daily (n = 20) or placebo (n = 17) for eight weeks. GABA levels in the dorsal anterior cingulate cortex were measured using proton magnetic resonance spectroscopy (1H-MRS) at baseline and follow-up. Published in Nutrients (PMID: 37960239; PMCID: PMC10649338).
Primary Finding
Compared to the placebo group, participants receiving kava showed a statistically significant reduction in dACC GABA at eight weeks (p = 0.049). Pairwise comparisons showed the kava group was 1.06 units lower than the placebo group at the follow-up measurement (p = 0.008). This was the first study to detect a measurable kava-induced change in central GABA levels in a clinical anxiety population using direct neuroimaging.
What the GABA Reduction Means
This finding is counterintuitive at first glance — if GABA is calming, why does a reduction correspond with anxiolytic treatment? The researchers offer a likely explanation: elevated dACC GABA in people with GAD may reflect a compensatory or dysregulated response to chronic anxiety. The reduction following kava treatment may signal a normalization of the system, an inhibitory recalibration rather than simple suppression. Baseline HAM-A anxiety scores were positively correlated with dACC GABA levels, supporting this interpretation.
Significance for Research
The authors note that dACC GABA levels, previously unexamined in GAD samples, could serve as a biomarker for both diagnosis and treatment response. This opens a pathway for more precise research into kava's mechanism — and into identifying which patients are most likely to respond to kava treatment based on measurable neurobiological markers.
The bottom line: For the first time, direct brain imaging confirmed that kava produces measurable changes in GABA chemistry in a clinically anxious population. The direction of the change — a reduction in elevated dACC GABA — is consistent with a normalizing rather than blunting effect, which may explain why kava reduces anxiety without the cognitive impairment seen with alcohol or benzodiazepines.
Part Three

What kavalactones actually do

The mechanism behind the effect

Kava root contains at least six major kavalactones: kavain, dihydrokavain, methysticin, dihydromethysticin, yangonin, and desmethoxyyangonin. These are the compounds responsible for kava's effects, and they don't all work the same way. Kavain and dihydrokavain carry most of the anxiolytic activity. Methysticin and dihydromethysticin contribute to muscle relaxation. Yangonin has been studied for its mood-related properties.

A 2016 study published in PLOS ONE by Olsen and colleagues provided the first direct experimental evidence that kavain — the major anxiolytic kavalactone — positively modulates GABA-A receptors at multiple subunit configurations. Using human recombinant receptors expressed in Xenopus oocytes, researchers showed that kavain enhanced GABA-A receptor activity across all receptor subtypes tested, with greater effect at extrasynaptic receptor configurations (α4β2δ) than at the synaptic type more typically targeted by benzodiazepines (α1β2γ2L). This subunit selectivity is significant: it suggests kavalactones may produce anxiolytic effects through a different receptor pathway than benzodiazepines, which could account for kava's notably different side-effect profile.

Beyond the GABA system, kavalactones have been found to block voltage-gated sodium channels, inhibit calcium channel-mediated excitatory neurotransmitter release, reversibly inhibit monoamine oxidase B, and reduce noradrenaline reuptake in the prefrontal cortex. The noradrenergic effect is particularly relevant to understanding kava's social profile. Reduced noradrenaline reuptake in the prefrontal cortex — the region responsible for emotional regulation and social cognition — may be part of why kava users describe social ease without impaired thinking. It's a different combination of effects than alcohol, acting on overlapping but distinct systems.

Mechanistic Evidence  ·  Olsen et al., 2016
Study Design
In vitro characterization of kavain at nine human recombinant GABA-A receptor subtypes expressed in Xenopus oocytes using two-electrode voltage clamp electrophysiology. First experimental evidence of direct kavalactone-GABA-A receptor interaction. Published in PLOS ONE (PMID: 27310720; PMCID: PMC4917254).
Key Finding
Kavain positively modulated all nine GABA-A receptor subtypes tested. Enhancement was greater at extrasynaptic α4β2δ receptors than at synaptic α1β2γ2L receptors — the subtype most commonly targeted by benzodiazepines. This subunit selectivity distinguishes kava's GABA mechanism from that of pharmaceutical anxiolytics and may explain the difference in cognitive side effects.
What This Means in Practice
Benzodiazepines bind with high affinity to synaptic GABA-A receptors and produce broad sedation, motor impairment, and dependence risk. Kavain's greater activity at extrasynaptic receptor subtypes suggests a pharmacologically distinct mechanism — one that may deliver anxiolytic effects without the same pattern of impairment. This remains an active area of research, but the receptor-level data supports what clinical trials and generations of kava drinkers have observed.
The bottom line: Kavalactones interact with GABA-A receptors, but not the same way benzodiazepines do. Their preference for extrasynaptic receptor subtypes may be a significant part of why kava produces relaxation without the sedation, motor impairment, and dependence risk associated with pharmaceutical anxiolytics and alcohol.
Part Four

Kava versus alcohol: same system, different story

Why the mechanism of action matters for what happens the morning after

Alcohol's anxiolytic and social effects come primarily from its action on the GABA system — specifically, it directly binds to and potentiates GABA-A receptors across the brain, while simultaneously inhibiting NMDA glutamate receptors. This combination quickly reduces anxiety and social inhibition. It also impairs motor coordination, slows reaction time, disrupts memory formation, and dehydrates the body. With chronic use, the brain compensates by downregulating GABA receptors and upregulating glutamate receptors, creating the neurobiological basis for tolerance and physical dependence.

None of that has been observed with kava. The kavalactone-GABA interaction is pharmacologically distinct, working more selectively and at lower receptor affinity than alcohol. Kava does not directly bind GABA receptors the way alcohol does. Clinical trials of kava have not found liver enzyme changes in short-term use with noble cultivar aqueous extracts, no evidence of cognitive impairment during or after use, and no signs of physical dependence. The 2018 systematic review by Ooi and colleagues analyzed 11 clinical trials and found no significant difference between kava and placebo in adverse event rates (p = 0.574).

There is one genuine safety consideration worth addressing clearly: hepatotoxicity concerns raised in the early 2000s, which led to bans on kava in several European countries. These cases were later found to be largely attributable to the use of non-noble cultivars, above-ground plant parts (leaves and stems rather than root), or kava extracted using acetone or ethanol solvents rather than water. Noble cultivar rootstock aqueous extract — the type used in the clinical trials referenced in this journal — has not been associated with liver toxicity in the reviewed literature, and a German administrative court overturned the German kava ban on these grounds. The distinction between preparation methods matters.

Safety Evidence  ·  Ooi et al., 2018
Study Design
Systematic review and meta-analysis of 11 randomized clinical trials of kava for anxiety. Databases searched: PubMed, CINAHL, PsycINFO. Risk ratios for treatment response pooled from five trials (n = 330) using Mantel-Haenszel fixed-effects model. Published in Complementary Therapies in Clinical Practice (PMID: 30396607).
Efficacy Finding
Kava was more effective than placebo in three of seven trials. Pooled risk ratio from five trials: 1.50 (95% CI: 1.12–2.01) in favor of kava. Researchers noted greater effectiveness in younger and female populations.
Safety Finding
Adverse event rates were no different between kava and placebo groups (p = 0.574). Laboratory values assessing liver function showed no significant difference from baseline in the majority of trials, with exceptions in two studies. Authors note that hepatotoxicity risk is considered low for short-term use (under eight weeks) with appropriate preparation methods.
The bottom line: The same basic system. A fundamentally different mechanism. Clinical data consistently shows kava producing anxiolytic effects without the cognitive impairment, physical dependence, or next-day consequences associated with alcohol. Preparation method — noble cultivar, aqueous root extract — is relevant to both efficacy and safety.